Stem Cell-derived Nanovesicles for the Treatment of Pulmonary Hypertension: Are We There Yet?
Am J Respir Cell Mol Biol
.
2022 Jul;67(1):3-5.
doi: 10.1165/rcmb.2022-0078ED.
Authors
Elena A Goncharova
1
,
Laszlo Farkas
2
Affiliations
1
Division of Pulmonary, Critical Care and Sleep Medicine University of California, Davis School of Medicine Davis, California.
2
Department of Internal Medicine The Ohio State University Wexner Medical Center Columbus, Ohio.
PMID:
35522729
PMCID:
PMC9273228
DOI:
10.1165/rcmb.2022-0078ED
No abstract available
Publication types
Editorial
Research Support, N.I.H., Extramural
Comment
MeSH terms
Humans
Hypertension, Pulmonary*
Mesenchymal Stem Cells*
Stem Cells
Grants and funding
R01 HL113178/HL/NHLBI NIH HHS/United States
R01 HL130261/HL/NHLBI NIH HHS/United States
R01 HL139881/HL/NHLBI NIH HHS/United States
R01 HL150638/HL/NHLBI NIH HHS/United States